Today: The Regeneron Pharmaceuticals Inc. (REGN) Given “Buy” Rating at Roth Capital

The Regeneron Pharmaceuticals Inc. (REGN) Given “Buy” Rating at Roth Capital

Roth Capital reaffirmed their buy rating on shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) in a research report sent to investors on Tuesday morning. The brokerage currently has a $520.00 target price on the biopharmaceutical company’s stock.

Several other brokerages have also issued reports on REGN. Vetr raised shares of Regeneron Pharmaceuticals from a hold rating to a buy rating and set a $472.09 price target for the company in a report on Tuesday, August 2nd. Canaccord Genuity reissued a hold rating and issued a $450.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. Robert W. Baird lowered shares of Regeneron Pharmaceuticals from an outperform rating to a neutral rating and decreased their price target for the company from $505.00 to $448.00 in a report on Friday, August 5th. Cowen and Company reissued a hold rating and issued a $430.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. Finally, Brean Capital reaffirmed a buy rating and issued a $489.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $480.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 397.20 on Tuesday. The firm’s 50-day moving average is $403.67 and its 200 day moving average is $391.72. The firm has a market capitalization of $41.56 billion, a P/E ratio of 61.97 and a beta of 1.31. Regeneron Pharmaceuticals has a 52-week low of $329.09 and a 52-week high of $592.59.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.17. Regeneron Pharmaceuticals had a net margin of 15.65% and a return on equity of 23.77%. The company earned $1.21 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same quarter in the previous year, the business earned $2.89 EPS. The firm’s revenue was up 21.4% on a year-over-year basis. Equities analysts anticipate that Regeneron Pharmaceuticals will post $11.00 EPS for the current year.

In other news, Director Joseph L. Goldstein sold 2,125 shares of the company’s stock in a transaction that occurred on Friday, July 29th. The shares were sold at an average price of $425.00, for a total transaction of $903,125.00. Following the completion of the sale, the director now owns 15,125 shares of the company’s stock, valued at approximately $6,428,125. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 10.40% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Meiji Yasuda Asset Management Co Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 1.2% in the first quarter. Meiji Yasuda Asset Management Co Ltd. now owns 852 shares of the biopharmaceutical company’s stock worth $307,000 after buying an additional 10 shares during the period. Wetherby Asset Management Inc. increased its stake in shares of Regeneron Pharmaceuticals by 2.3% in the second quarter. Wetherby Asset Management Inc. now owns 796 shares of the biopharmaceutical company’s stock worth $278,000 after buying an additional 18 shares during the period. Fagan Associates Inc. increased its stake in shares of Regeneron Pharmaceuticals by 2.5% in the second quarter. Fagan Associates Inc. now owns 820 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 20 shares during the period. American Money Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 3.3% in the second quarter. American Money Management LLC now owns 785 shares of the biopharmaceutical company’s stock worth $274,000 after buying an additional 25 shares during the period. Finally, Cleararc Capital Inc. increased its stake in shares of Regeneron Pharmaceuticals by 1.4% in the first quarter. Cleararc Capital Inc. now owns 1,909 shares of the biopharmaceutical company’s stock worth $688,000 after buying an additional 26 shares during the period. 68.16% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Related posts

Leave a Comment